Investigational drug · Phase 3
HDM1702
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Obesity Control.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 25, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "HDM1702"
First trial start
2025
Jan 3, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HDM1702", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obesity Control
Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "HDM1702" as an intervention, largest first.
- Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese PatientsPivotal-lookingRecruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT07036172 · 460 participants (planned) · Start Jan 3, 2025 · Primary completion Apr 2026
Drug: HDM1702; Wegovy ® · For: Obesity Control
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.